DURHAM, N.C., Jan. 29, 2019 /PRNewswire/ -- 410 Medical, Inc., a medical device company focused on helping providers rapidly address hypotension and shock in critically ill patients, today announced a recent publication in Journal of Infusion Nursing. Use of the push-pull technique, a commonly used method of fluid resuscitation in children, resulted in an average of 23 aseptic violations for each 500mL fluid bolus. In contrast, use of LifeFlow, a new simple device for rapid, controlled delivery of a fluid bolus, resulted in less than one aseptic violations per bolus.
More than 250,000 catheter-related bloodstream infections (CLABSI's) occur annually in the United States, resulting in significant morbidity and mortality. Although the frequency of CLABSI's are low, one CLABSI can result in excess hospital costs of $70,000 and subjects patients to a two-fold increase in the risk of death. The article titled "Improving Aseptic Technique During the Treatment of Pediatric Septic Shock"and published in the January/February edition of the Journal of Infusion Nursing details a study evaluating the aseptic violations associated with rapid infusion of 500mL of crystalloids in a pediatric simulation model. Given the known risk of having contaminants in a sterile syringe, this result demonstrates that the push-pull technique may introduce a higher risk of syringe contamination and, subsequently, hospital-acquired infection (HAI).
"There are several studies that have shown that repeated cycling of a syringe increases the contamination risk, " said Galen Robertson, medical device engineer and Chief Operating Officer of 410 Medical. "With LifeFlow, providers have a faster, simpler and safer tool for delivery of fluids in critically ill patients. Designed with a protective enclosure, LifeFlow shields the syringe from the contamination associated with repeated use and handling of a single syringe."
About 410 Medical, Inc.
410 Medical is dedicated to developing innovative products that help emergency clinicians provide better care for critically ill patients. 410 Medical's first product, LifeFlow, is designed to enhance the speed and efficiency of fluid resuscitation, improving care for patients with life-threatening conditions such as shock and sepsis. LifeFlow received FDA clearance for human use in 2016. For more information, visit www.410medical.com.
SOURCE 410 Medical, Inc.